Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
NCT ID: NCT05828719
Last Updated: 2025-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
900 participants
INTERVENTIONAL
2023-06-16
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
NCT06930092
Long-term Outcomes and Prognostic Factors in Patient Undergoing CABG or PCI
NCT03870815
Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology
NCT06243653
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
NCT06566183
Prospective Pecutaneous Coronary Intervention Registry
NCT05624905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Percutaneous coronary intervention (PCI) is another intervention that is commonly used to revascularize significant coronary stenosis. Despite common belief that revascularization by PCI would improve perfusion to ischemic myocardium and improve clinical outcomes, several clinical trials have failed to show beneficial impact of PCI over OMT in stable ischemic heart disease other than symptomatic improvement. Recently published REVIVED trial compared effect of PCI and OMT in ischemic cardiomyopathy patients with left ventricular ejection fraction \< 35% and demonstrable viable myocardial segments, and found no significant difference in clinical outcomes of both groups.
However, whether PCI optimized by additional information can make a difference in this setting remains unanswered. It is known that intravascular imaging and coronary physiologic testing using intravascular ultrasound (IVUS), optical coherence tomography (OCT) or fractional flow reserve (FFR) result in better outcomes compared to conventional angiography alone. IVUS provides anatomical information regarding the lumen, plaque, and plaque characteristics, and can optimize stent placement minimizing stent-related problems and lead to better outcomes. On the other hand, FFR provides information on amount of ischemia which the stenosis in question is causing, and also improves the quality of PCI which has been demonstrated by multiple previous trials. Unfortunately, proportion of IVUS and FFR use is not disclosed in REVIVED trial, and it is possible there is a room for improvement if the PCI is further guided by these adjunctive diagnostic procedures in regard to the clinical outcomes.
In this regard, it is our hypothesis that PCI guided and optimized by intravascular imaging and FFR-guided strategy would bring additional benefit that may result in significant difference of prognosis for ischemic cardiomyopathy compared to OMT alone. Randomized controlled trial to test this hypothesis would provide valuable evidence to guide treatment strategy for ischemic cardiomyopathy. Therefore, RESTORE-PCI trial has been designed to compare clinical outcomes after state-of-the-art PCI or OMT for ischemic cardiomyopathy.
The aim of the study is to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction. Primary hypothesis is that revascularization guided by invasive physiologic indexes and optimized by intravascular imaging device plus optimal medical treatment (OMT) would reduce risk of primary composite end point (major adverse cardiac events \[MACE\], a composite of death, myocardial infarction (MI), admission for heart failure, or advanced heart failure requiring LVAD or transplantation) than OMT alone in patients with ischemic cardiomyopathy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Guideline-directed medical treatment group
In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC/AHA/SCAI or ESC/EACTS guidelines for heart failure.
No interventions assigned to this group
Revascularization group
In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC/AHA/SCAI or ESC/EACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization.
Revascularization criteria is presented as below. Revascularization indication
1. Diameter stenosis \>90% by visual assessment
2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)
3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.
* Left main artery
* Proximal to mid left anterior descending artery
* Proximal left circumflex artery in left dominant coronary arterial system
* Proximal to distal right coronary artery in right dominant coronary arterial system
Percutaneous coronary intervention
Revascularization indication
1. Diameter stenosis \>90% by visual assessment
2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)
3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.
* Left main artery
* Proximal to mid left anterior descending artery
* Proximal left circumflex artery in left dominant coronary arterial system
* Proximal to distal right coronary artery in right dominant coronary arterial system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Percutaneous coronary intervention
Revascularization indication
1. Diameter stenosis \>90% by visual assessment
2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)
3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.
* Left main artery
* Proximal to mid left anterior descending artery
* Proximal left circumflex artery in left dominant coronary arterial system
* Proximal to distal right coronary artery in right dominant coronary arterial system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with stage C heart failure and left ventricular ejection fraction\<40%
* Patients with significant coronary artery stenosis (diameter stenosis\>50% with proven inducible myocardial ischemia by invasive physiologic assessment)
* Coronary artery disease is amenable for percutaneous coronary intervention (PCI)
* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
Exclusion Criteria
* Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography)
* Target lesions not amenable for PCI by operators' decision
* Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization
* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
* Pregnancy or breast feeding
* Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
* Unwillingness or inability to comply with the procedures described in this protocol.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young Bin Song
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young Bin Song, MD, PhD
Role: STUDY_CHAIR
Samsung Medical Center
Young Bin Song, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Joo Myung Lee, MD, MPH, PhD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsune Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RESTORE119023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.